Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HuMAB companies -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (663)	8/10/2004 12:05:01 PM
From: keokalani'nui	Read Replies (1) \| Respond to of 1022

Not cat, not morph, not dyax, not medx, not cll. pdli can't do fully human. abgx? Currently, Abgenix has three ongoing collaborations with Amgen: a codevelopment collaboration for ABX-EGF, a technology licensing agreement through which Amgen has advanced an antibody product candidate into clinical trials, and a discovery and development arrangement focused on developing antibodies to novel oncology targets. Also, from 2001 abgx 10k: Amgen: In April 1999, we entered into a research collaboration agreement with Amgen Inc., to generate fully human antibodies to an undisclosed antigen target. In 2000, Amgen exercised its option to acquire a product license. In December 2000, we extended our agreement to generate fully human antibodies to multiple antigen targets to be supplied by Amgen, during a five-year term. Also provided in the April 1999 agreement, Abgenix will perform the immunizations and certain research activities.